MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Metrnl

  • Home
  • Metrnl
Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury
Posted inCardiology Hematology-Oncology news

Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury

Posted by MedXY By MedXY 08/21/2026
Metrnl reduces platelet activation and thrombus formation by promoting CD36 degradation, offering a promising therapeutic strategy for thrombotic diseases including acute myocardial infarction without increasing bleeding risk.
Read More
  • Impact of Palate Repair Timing within First 15 Months on Early Speech Development in Children with Cleft Palate
  • Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer
  • Enhancing Vestibular Migraine Rehabilitation with Virtual Reality: A Randomized Controlled Trial
  • Expanding Pediatric Cochlear Implant Indications: Multicenter Evidence Supports Safety and Efficacy in Younger Children and Those with Residual Hearing
  • Impact of Trauma on Social Risk: Insights from Serial Hospital Data Screening
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top